| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801587202010 | 158720201 | FELDENE DISP.TAB 20MG/TAB BTX10(1BLISTERX10) | 1.54 | 1.62 | 2.24 |
| 05/2018 | 2801587203017 | 158720301 | FELDENE DISP.TAB 10MG/TAB BTX20(2 BLISTERX10) | 2.22 | 2.33 | 3.21 |
For treatment of osteoarthritis and rheumatoid arthritis.
The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.
Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
Well absorbed following oral administration.
30 to 86 hours
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.
* 0.14 L/kg